Targeting EP2 receptors to improve treatment for ischemic stroke
Official title: EP2 Antagonists for Ischemic Stroke
Funded at University of Tennessee Health Sci Ctr · NIH-10907027 · Data updated 2026-11-12
This study is looking at new medications that could help people who have had an ischemic stroke by targeting a specific part of the brain involved in inflammation and injury, with the goal of finding safer and more effective treatments to use right after a stroke happens.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $367,070 |
| NIH project number | 5R61NS130199-02 |
| Project ID | NIH-10907027 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults who have experienced an ischemic stroke or are at risk of having one.
✕Less likely to help
Patients who have other types of strokes, such as hemorrhagic strokes, may not benefit from this research.
What this research studies
This research investigates the role of EP2 antagonists in treating ischemic stroke, a condition that affects a significant number of adults and can lead to severe disabilities or death. The study aims to develop new medications that can safely target the EP2 receptor, which is involved in brain inflammation and injury following a stroke. By focusing on this specific pathway, the researchers hope to create more effective treatments that can be administered within the critical time window after a stroke occurs. The approach involves understanding the biochemical mechanisms of stroke and testing new drug candidates that can penetrate the brain effectively.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients suffering from ischemic stroke.
How similar studies have gone: Previous research has shown promise in targeting inflammatory pathways in stroke treatment, suggesting that this approach could be a meaningful advancement.
Where this research is happening
-
University of Tennessee Health Sci Ctr
Memphis, United States Active
Researchers
- Principal investigator: Jiang, Jianxiong — University of Tennessee Health Sci Ctr
- Study coordinator: Jiang, Jianxiong
Related research
Other NIH-funded projects on the same topics.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
Genetic testing to find causes of early-onset ischemic stroke
This project uses whole-exome sequencing to look for gene changes that may cause ischemic stroke in adults who had a stroke at a young age.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
How biological aging and blood proteins relate to thinking after a stroke
This project looks at whether measures of biological aging and patterns of blood proteins help explain which stroke survivors keep their thinking sharp and which go on to develop vascular dementia.
-
Repurposing NEXLETOL to treat ischemic stroke
Aims to see if the cholesterol drug NEXLETOL can help people after an ischemic stroke by supporting brain energy use and reducing injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.